Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

CYDY Insider Trading

CytoDyn Inc. | Pharmaceutical Preparations

Comprehensive Trading Performance Summary

The investment history of corporate insiders at CytoDyn Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2020-12-29 03:21 2020-12-22 Mulholland Michael D. Officer - Chief Financial Officer OPT+S $6.23 711,801 $4,437,581 284,081 0.0%
2020-12-22 05:55 2020-12-17 Mulholland Michael D. Officer - Chief Financial Officer OPT+S $5.27 1,104,799 $5,827,041 284,081 0.0%
2020-11-04 05:09 2020-11-02 Naydenov Jordan G Director BUY $2.57 193,500 $497,295 6,451,323 +3.1%
2020-10-27 02:54 2020-10-23 Colachis Arian Officer - GC and Corporate Secretary BUY $2.50 10,000 $25,000 80,000 +14.3%
2020-10-27 02:45 2020-10-23 Naydenov Jordan G Director BUY $2.49 120,000 $298,308 6,257,823 +2.0%
2020-05-06 04:27 2020-05-01 Kelly Scott A. Director, Officer - Chief Medical Officer OPT+S $3.26 1,200,000 $3,912,480 1,557,718 0.0%
2020-05-06 04:27 2020-05-01 Kelly Scott A. Director, Officer - Chief Medical Officer BUY $0.57 250,000 $141,250 1,847,302 +15.7%
2020-05-05 04:55 2020-04-30 Pourhassan Nader Director, Officer - President & CEO OPT+S $3.27 4,821,174 $15,760,900 908,343 0.0%
2016-10-21 23:06 2016-10-21 Pourhassan Nader Director, Officer - President and CEO BUY $0.66 15,000 $9,930 15,750 +2,000.0%
2016-10-17 23:01 2016-10-17 Mulholland Michael D. Officer - CFO, Treasurer and Secretary BUY $0.66 11,000 $7,238 37,043 +42.2%
2015-07-20 19:24 2015-05-05 ALPHA ADVISORS, LLC 10% owner, Other BUY $0.50 140,843 $70,422 2,236,543 +6.7%
2015-07-16 00:05 2015-05-05 DOCKERY CARL Director, 10% owner BUY $0.50 140,843 $70,422 2,236,543 +6.7%
2014-11-01 00:05 2014-10-30 Caracciolo Anthony Director BUY $0.72 26,000 $18,720 88,136 +41.8%
2014-10-16 21:10 2014-10-15 Mulholland Michael D. Officer - CFO, Treasurer and Secretary BUY $0.79 2,500 $1,975 26,043 +10.6%
2012-09-22 04:05 2012-09-19 Dembow George F Director SELL $0.79 75,000 $59,003 249,205 -23.1%
2012-05-10 00:44 2012-05-07 Dembow George F Director SELL $2.02 7,175 $14,494 317,216 -2.2%
2012-05-03 22:46 2012-05-01 Dembow George F Director SELL $2.06 13,509 $27,858 324,391 -4.0%
2012-04-30 23:16 2012-04-26 Van Ness Kenneth Director, Officer, 10% owner - President & CEO SELL $2.10 1,396 $2,932 1,927,645 -0.1%
2012-01-25 23:59 2012-01-24 Dembow George F Director SELL $2.71 30,000 $81,300 337,500 -8.2%
2011-12-22 22:24 2011-12-21 CARACCIOLO ANTHONY Director BUY $1.50 50,000 $75,000 50,000 +100.0%
2011-11-03 19:16 2008-06-19 Dembow George F Director SELL $0.51 7,500 $3,825 367,900 -2.0%
2011-11-03 01:33 2009-10-01 Van Ness Kenneth Director, Officer, 10% owner - CEO & President BUY $0.90 728,000 $655,200 728,000 +100.0%
2011-11-03 01:33 2009-05-22 Van Ness Kenneth Director, Officer, 10% owner - CEO & President SELL $1.07 110,959 $118,449 1,929,041 -5.4%
2009-11-18 01:52 2009-11-13 ALLEN ALLEN D Director, Officer, 10% owner - Chief Executive Officer SELL $0.50 300,000 $150,000 1,403,515 -17.6%
2009-09-29 22:36 2009-07-01 Naydenov Jordan G Director BUY $0.50 606,400 $303,200 606,400 +100.0%
2007-06-27 23:24 2007-06-22 ALLEN CORINNE E Director, Officer, 10% owner - Vice President BUY $0.63 2,000 $1,250 1,575,521 +0.1%
2007-05-21 21:34 2007-05-21 ALLEN CORINNE E Director, Officer, 10% owner - Vice President BUY $0.55 2,500 $1,375 1,428,521 +0.2%
SHOW ENTRIES

How to Interpret $CYDY Trades

Not every insider transaction in CytoDyn Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $CYDY shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for CYDY

Insider activity data for CytoDyn Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $CYDY, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.